By Dr. Elizabeth Yan Zhang, CMQ/OE, MBA, PhD, Founder and CEO, GeneGoCell on August 24, 2026
Explore how CAR therapy is moving beyond cancer toward autoimmune immune reset and in vivo engineering, and why analytical characterization must evolve with it.